Biopharmaceutical company CStone Pharmaceuticals (HKEX:2616) on Friday announced European Commission approval of sugemalimab (Cejemly) in combination with platinum-based chemotherapy for first-line treatment of non-small cell lung cancer (NSCLC).
The drug becomes the first Chinese-developed anti-PD-L1 monoclonal antibody approved in Europe.
This approval was based on the GEMSTONE-302 Phase 3 trial, which demonstrated improved survival rates.
CStone has partnered with Swiss pharmaceutical company Ewopharma for commercialisation in Central and Eastern Europe and in Switzerland. The company is seeking further partnerships for Western Europe and other regions.
CStone plans to submit additional applications to the European Medicines Agency for indications in other cancer types.
Indivior updates on Aelis Farma's Phase 2B study of AEF0117 for Cannabis Use Disorder
Vesper Bio announces positive Phase I results for FTD treatment
Empower Pharmacy names new president
Innovent's IBI363 receives US FDA Fast Track Designation
Valneva and Pfizer report positive Phase 2 booster results for Lyme disease vaccine
Grit Biotechnology's GT201 receives US FDA IND approval
Cereno Scientific doses first patient in Expanded Access Program for PAH
Medicilon USA begins operations at second R&D centre in Massachusetts
CS Genetics names new chief operating officer and chief scientific officer
Expanse Medical names new chief executive officer and FlowPhysix board member